这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associate...
4、Collins DM, Conlon NT, Kannan S, et al. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers (Basel). 20...
[9]Mutai R, Barkan T, Moore A, et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast. 2021 Dec;60:62-69. [10]Eiger D, Agostinetto E, Saúde-Conde R, et al. The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers (Base...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
[1] Bazell R. Her-2: The making of herceptin, a revolutionary treatment for breast cancer[M]. Random House, 2011. [2] EsTEva F J, Hortobagyi G N. Gaining ground on breast cancer[J]. Scientific American, 2008, 298(6): 58-65. ...
[12]Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. ...
3. Modi S, Jacot W, Iwata H, et al. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study[J]....
8、Ma,Fei et al.“Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer(PHILA):randomised,double blind,multicentre,phase 3 trial.”BMJ(Clinical research ed.)vol.383 e076065.31 Oct.2023,doi:10.1136/bmj...
10.Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. ...
in the clinical trials that have gotten us where we are in the treatment of HER2-positive cancers. The ongoing and planned areas of research in this field will continue to lead us into the future in which even more women with HER2-positive breast cancer will live longer or even be cured....